To determine the effects of SHIP1 inhibition on CLL in an immunocompetent system, we again used the TCL1tg CLL mouse model33, which is an established tool for studying therapeutic targets in human CLL47. This evidence concerns the gene INPP5D and B-cell chronic lymphocytic leukemia.